MSB Trading 2020 - a new dawn, page-11961

I wonder what level of involvement Novartis would have if these discussions are taking place? They now have a vested interest but possibly MSB have a contractual obligation to involve them at some level.

SI's quote from very early on in the P3 trial, just after the CR, has stayed with me. In referring to EUA he said something along the lines of 'the FDA are looking not just for efficacy but the ability to manufacture the quantities required for EUA'. That's where Novartis may be called in along with the fact that they have committed to helping with cQA's as well as possibly using this C-19 ARDS data for the ex C-19 ARDS indications in future trials. My hope is their experience and reputation will be add more credibility to the EUA application with the FDA as well as take some load off the regulatory team at MSB who must be working around the clock, atm.